Abstract
Tumor necrosis factor-alpha (TauNuFalpha) blockers are effective in the treatment of inflammatory arthritis but can induce autoimmune disorders including multiple sclerosis. Described are two patients who developed chronic inflammatory demyelinating polyneuropathy after initiation of anti-TNFalpha treatment.
Publication types
-
Case Reports
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Aged
-
Antibodies, Monoclonal / adverse effects
-
Antirheumatic Agents / adverse effects*
-
Arthritis, Rheumatoid / drug therapy
-
Autoantibodies / drug effects
-
Autoantibodies / immunology
-
Etanercept
-
Female
-
G(M1) Ganglioside / immunology
-
Humans
-
Immunoglobulin G / adverse effects
-
Infliximab
-
Male
-
Middle Aged
-
Muscle Weakness / chemically induced
-
Muscle Weakness / immunology
-
Muscle Weakness / physiopathology
-
Neural Conduction / drug effects
-
Neural Conduction / immunology
-
Peripheral Nerves / drug effects*
-
Peripheral Nerves / immunology
-
Peripheral Nerves / physiopathology
-
Polyradiculoneuropathy, Chronic Inflammatory Demyelinating / chemically induced*
-
Polyradiculoneuropathy, Chronic Inflammatory Demyelinating / immunology
-
Polyradiculoneuropathy, Chronic Inflammatory Demyelinating / physiopathology
-
Receptors, Tumor Necrosis Factor
-
Recovery of Function / immunology
-
Sensation Disorders / chemically induced
-
Sensation Disorders / immunology
-
Sensation Disorders / physiopathology
-
Spondylitis, Ankylosing / drug therapy
-
Tumor Necrosis Factor-alpha / antagonists & inhibitors*
Substances
-
Antibodies, Monoclonal
-
Antirheumatic Agents
-
Autoantibodies
-
Immunoglobulin G
-
Receptors, Tumor Necrosis Factor
-
Tumor Necrosis Factor-alpha
-
G(M1) Ganglioside
-
Infliximab
-
Etanercept